Cellular Therapy and Hematologic Malignancies Grand Rounds Date of Lecture: May 6, 2014 Learning Title of Lecture: Journal Club: Outcome of Donor Lymphocyte Infusion after T Cell-depleted Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndromes. Krishnamurthy P, et al. Biol Blood Marrow Transplant 19 (2013):562-568. Objectives: Following this activity series, learners should be able to: 1. Appreciate ongoing research activities within the DCI Hematologic Malignancies and Cellular Therapy program; 2. Learn recent research developments in Hematologic Malignancies and Cellular Therapy from national and international renowned experts; 3. Promote interactions and collaborations among members of the program. Speaker: Mitchell Horwitz, M.D. Time: 12:00 p.m. -1:00 p.m. Location: CR 7015 –North Pavilion ; Faculty (Speaker) Disclosure: Dr. Mitchell Horwitz discloses the following personal/financial relationships which are relevant to this activity: Advisory Board Member for Genzyme; Principal Investigator for Otsuka and Pfizer. Activity Medical Director/Planning Committee Disclosure(s): Dr. Mitchell Horwitz discloses the following personal/financial relationships which are relevant to this activity: Advisory Board Member for Genzyme; Principal Investigator for Otsuka and Pfizer. Accreditation: The Duke University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Credit Designation: The Duke University School of Medicine designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s). Physicians should only claim credit commensurate with the extent of their participation in the activity. Unapproved Use Disclosure: Duke School of Medicine requires CME faculty (speakers) to disclose to the attendees: 1) When products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and 2) Any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty at this symposium may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information. You must text the six letter code provided by the speaker to (919)213-8033 to receive credit for attending this conference.